Kiniksa Pharmaceuticals, Ltd. (KNSA) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Hamilton, Bermuda. 現CEOは Sanj K. Patel.
KNSA を有する IPO日 2018-05-25, 315 名の正社員, に上場 NASDAQ Global Select, 時価総額 $3.48B.
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing innovative therapeutic medicines for patients with debilitating diseases that have significant unmet medical needs. The company's product portfolio includes ARCALYST, an approved treatment for recurrent pericarditis, along with several clinical-stage candidates including Mavrilimumab for giant cell arteritis, Vixarelimab for prurigo nodularis, and KPL-404 targeting immune-mediated disorders. Founded in 2015 and headquartered in Hamilton, Bermuda, Kiniksa is committed to addressing serious inflammatory and immunological conditions with limited existing treatment options.
